Table 2.
Trial-Directed Therapy | Post-Trial Surveillance | |||
---|---|---|---|---|
CHC Level Nadir after Treatment Initiation | CHC Levels by End of Treatment | Evidence of Progression | CHC Levels | |
Patient 2 | Undetectable | Undetectable | Yes | Increased |
Patient 3 | Undetectable | Undetectable | No | Undetectable |
Patient 4 | Undetectable | Undetectable | Yes | Increased |
Patient 1 | Undetectable | Increased | N/A | N/A |
Patient 5 | Undetectable | Increased | Yes | Increased |
Abbreviations: CHC, circulating hybrid cells. Response and resistance determined by multidisciplinary interpretation of standard-of-care carbohydrate antigen (CA) 19-9 and cross-sectional imaging measures (Figure S2) for each patient.